Pharmaceutical Approval Update.

Article Details

Citation
Copy to clipboard

Kaufman MB

Pharmaceutical Approval Update.

P T. 2017 Sep;42(9):562-580.

PubMed ID
28890641 [ View in PubMed
]
Abstract

Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.

DrugBank Data that Cites this Article

Drugs